Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or North Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to North Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. North Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Bob Wodecki (NPI 1649270190)

Field	Value
Entity Type	Individual
Organization	Bob Wodecki
Address	293 Old Mocksville Rd
City	Statesville
State	NC
ZIP	28625
Taxonomy	Rheumatology Physician
NPI Enumerated	July 27, 2005

Payer Source	Total Paid
Medicare	$3.1M
Medicaid	$0

Key Findings

This provider’s Medicare activity is the dominant revenue source: lifetime Medicare revenue is $3.1M and there is no Medicaid billing on file, so the practice is effectively single‑payer with respect to public programs. The absence of Medicaid billing suggests limited exposure to Medicaid populations and that Medicare payment trends will drive payer negotiation leverage and revenue risk.

Revenue is highly concentrated in a small set of biologic infusion codes: the precomputed top 3 Medicare codes by revenue account for 67.3% of this provider's total Medicare revenue. Those top codes — J0129 (23K claims, $783.2K), J9312 (10.9K claims, $676.4K), and J3262 (123.7K claims, $618.3K) — indicate most dollars flow from clinic‑administered injectable biologic therapies.

The code mix and volumes point to an infusion‑centric rheumatology practice model: high claim counts for J3262 (123.7K claims, $618.3K) and J0129 (23K claims, $783.2K) together with chemotherapy/infusion administration codes (96413, 96415, 96365, 96367, 96375) show routine in‑office IV/subcutaneous biologic and infusion services rather than primarily procedure‑only or consultative care. This suggests on‑site pharmacy handling, infusion nursing capacity, and workflow built around repeat biologic administrations.

Competitive standing varies by drug: the provider ranks highly for several biologics nationally — J9312 ranks #4 of 317 providers nationally (99th percentile; notably above typical national volume for this code) and J3262 ranks #27 of 618 (96th percentile; notably above typical national volume). In contrast, J0129 ranks #97 of 1221 (92th percentile; typical, unremarkable volume). These rankings imply the provider is a major national participant for rituximab and tocilizumab administrations but only a typical volume provider for abatacept.

Office visit activity is also unusually high relative to national peers: 99214 has 1.3K claims and $107K revenue and ranks #6229 of 479517 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). This pattern indicates substantial ongoing management of established patients in addition to infusion throughput, consistent with longitudinal rheumatology care.

Several ancillary service codes appear as outliers and reflect on the service mix: add‑on infusion hours 96415 is a 99th percentile extreme outlier, and radiographic codes 73110 and 73130 both rank in the 99th percentile (extreme outliers). These high ranks for extended infusion time and upper‑extremity imaging suggest the practice delivers prolonged infusion sessions and frequently evaluates musculoskeletal complaints in‑house.

The provider’s clinical tenure is long: NPI was enumerated on 2005-07-27 (~21 years ago), indicating a well‑established practice presence in STATESVILLE, NC. That longevity, combined with the concentrated biologics revenue base and high national ranks on key infusion codes, supports a stable, specialty infusion practice with entrenched referral or patient retention patterns.

From a payer and contracting perspective, this profile signals concentrated Medicare risk and negotiating focus: a small number of biologic administration codes produce most revenue (67.3% concentrated) and the provider has no Medicaid billing on file. Payors evaluating network value or utilization management should prioritize the high‑volume biologic codes (J9312, J3262, J0129) and the unusually high utilization of prolonged infusion and E/M services when modeling spend and designing oversight or reimbursement strategies.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

76 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	23,040	$30	$783.2K
J9312	Injection, rituximab, 10 mg	10,910	$60	$676.4K
J3262	Injection, tocilizumab, 1 mg	123,660	$10	$618.3K
J1602	Injection, golimumab, 1 mg, for intravenous use	32,170	$10	$321.7K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	7,580	$30	$197.2K
J0897	Injection, denosumab, 1 mg	6,360	$20	$114.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,260	$90	$107K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	710	$100	$70K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	600	$50	$28.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	440	$60	$26.2K

Showing 1–10 of 76

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 76 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. North Carolina Distribution

Bob Wodecki — 12 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — North Carolina

Full comparison — all codes billed, vs. state median

76 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	7	70	9,530	$30	$393.2K
J3262	3	40	37,160	$1	$224.8K
J9312	1	20	2,070	$60	$178.1K
J1602	11	70	11,900	$10	$175.9K
J1745	10	80	4,110	$30	$117.3K
86235	10	40	160	$20	$70.1K
J0897	61	430	2,100	$20	$63.9K
G0482	105	120	80	$190	$40.3K
80307	343	380	100	$60	$35.4K
86038	12	30	30	$10	$23K

Showing 1–10 of 76

Related Providers

Other providers that share a Tax Identification Number (TIN) with Bob Wodecki, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jerome Watson	NC	Physical Medicine & Rehabilitation Physician	$249.2K	$0
Jeffrey Brink	FL	Otolaryngology Physician	$223.5K	$0
John Allan	NC	Cardiovascular Disease Physician	$205.8K	$0
Rocco Tritico	NC	Specialist	$172.1K	$0
Yvette-marie Pellegrino	SC	Adult Medicine Physician	$132K	$0
Todd Hansen	FL	Phlebology Physician	$123.7K	$0
Dominick Carbone	NC	Urology Physician	$65.5K	$0
Julia Prokesova	CT	Emergency Medicine Physician	$59.8K	$0
William Newton	NC	Vascular Surgery Physician	$45.7K	$0
Zulfiqar Turk	NC	Neurology Physician	$38.6K	$0

Nearby Providers

Other providers in the same ZIP code as Bob Wodecki, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Homecare Management Corporation	NC	Community/Behavioral Health Agency	$0	$38.2M
Piedmont Healthcare, P.A.	NC	Internal Medicine Physician	$0	$34.1M
Addiction Recovery Medical Services	NC	Community/Behavioral Health Agency	$112.3K	$14.1M
Addiction Recovery Medical Services - Providers	NC	Pain Medicine (Anesthesiology) Physician	$0	$7.6M
Frank Lichtenberger	NC	Allergy & Immunology Physician	$653.5K	$0
Piedmont Healthcare, PA	NC	Endoscopy Clinic/Center	$353K	$162.4K
Ahmed Elnaggar	NC	Pulmonary Disease Physician	$197.7K	$0
Roger Hatharasinghe	NC	Internal Medicine Physician	$177K	$0
Harsh Govil	NC	Interventional Pain Medicine Physician	$174.9K	$0
Robert Aryeetey	NC	Infectious Disease Physician	$171.7K	$0

Bob Wodecki — Billing Profile & Reimbursement Data

Sign up for Bob Wodecki — Billing Profile & Reimbursement Data policy alerts

Bob Wodecki — Billing Profile & Reimbursement Data

Sign up for Bob Wodecki — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References